In a multistage process that involves moving from a precancerous lesion to a malignant tumour state, cancer develops when normal cells undergo the change into tumour cells. Colon cancer, also known as colorectal cancer (CRC), is the third most common and second-deadliest malignant tumour in the world. The current study's objective was to assess the anticancer potential of a methanolic extract of Coleus forskohlii root on the cancer cell line HT-29 using the MTT assay. A variety of assay methods were used, including morphological investigations, cell growth inhibition, and cell viability. At various concentrations (12.5, 25, 50, 100, and 200 µg/ml), the Coleus forskohlii extract was tested against the HT-29 cell line for its ability to inhibit cell proliferation. This study revealed that when concentrations rise the cell growth inhibition levels rise. The conventional medicine Doxorubicin had a growth inhibition of 72.70% at a dose of 5 µg/ml while the lowest growth inhibition was determined to be 9.55% at 12.5 µg/ml and the highest growth inhibition was 71.16% at 200 µg/ml. IC50 was greater than 123.90 µg/ml. According to the study's findings, a human colon adenocarcinoma cell line could be resistant to the anti-colorectal cancer effects of Coleus forskohlii root methanolic extract (HT-29).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.